Wang Tao, Wang Shu, Li Zhuolin, Xie Jie, Chen Huan, Hou Jing
Research Laboratory Center, Guizhou Provincial People's Hospital, Guiyang, China.
Department of Breast Surgery, Guizhou Provincial People's Hospital, Guiyang, China.
Front Immunol. 2024 Nov 19;15:1485123. doi: 10.3389/fimmu.2024.1485123. eCollection 2024.
Breast cancer, characterized by its heterogeneity, is a leading cause of mortality among women. The study aims to develop a Machine Learning-Derived Liquid-Liquid Phase Separation (MDLS) model to enhance the prognostic accuracy and personalized treatment strategies for breast cancer patients.
The study employed ten machine learning algorithms to construct 108 algorithm combinations for the MDLS model. The robustness of the model was evaluated using multi-omics and single-cell data across 14 breast cancer cohorts, involving 9,723 patients. Genetic mutation, copy number alterations, and single-cell RNA sequencing were analyzed to understand the molecular mechanisms and predictive capabilities of the MDLS model. Immunotherapy targets were predicted by evaluating immune cell infiltration and immune checkpoint expression. Chemotherapy targets were identified through correlation analysis and drug responsiveness prediction.
The MDLS model demonstrated superior prognostic power, with a mean C-index of 0.649, outperforming 69 published signatures across ten cohorts. High-MDLS patients exhibited higher tumor mutation burden and distinct genomic alterations, including significant gene amplifications and deletions. Single-cell analysis revealed higher MDLS activity in tumor-aneuploid cells and identified key regulatory factors involved in MDLS progression. Cell-cell communication analysis indicated stronger interactions in high-MDLS groups, and immunotherapy response evaluation showed better outcomes for low-MDLS patients.
The MDLS model offers a robust and precise tool for predicting breast cancer prognosis and tailoring personalized treatment strategies. Its integration of multi-omics and machine learning highlights its potential clinical applications, particularly in improving the effectiveness of immunotherapy and identifying therapeutic targets for high-MDLS patients.
乳腺癌具有异质性,是女性死亡的主要原因。本研究旨在开发一种机器学习衍生的液-液相分离(MDLS)模型,以提高乳腺癌患者的预后准确性和个性化治疗策略。
本研究采用十种机器学习算法为MDLS模型构建108种算法组合。使用来自14个乳腺癌队列的9723例患者的多组学和单细胞数据评估模型的稳健性。分析基因突变、拷贝数改变和单细胞RNA测序,以了解MDLS模型的分子机制和预测能力。通过评估免疫细胞浸润和免疫检查点表达来预测免疫治疗靶点。通过相关性分析和药物反应性预测确定化疗靶点。
MDLS模型显示出卓越的预后能力,平均C指数为0.649,在十个队列中优于69个已发表的特征。高MDLS患者表现出更高的肿瘤突变负担和独特的基因组改变,包括显著的基因扩增和缺失。单细胞分析显示肿瘤非整倍体细胞中MDLS活性更高,并确定了参与MDLS进展的关键调节因子。细胞间通讯分析表明高MDLS组中的相互作用更强,免疫治疗反应评估显示低MDLS患者的预后更好。
MDLS模型为预测乳腺癌预后和制定个性化治疗策略提供了一种强大而精确的工具。其多组学和机器学习的整合突出了其潜在的临床应用,特别是在提高免疫治疗的有效性和确定高MDLS患者的治疗靶点方面。